These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 16509929)
1. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Ito T; Tanimoto M; Yamada K; Kaneko S; Matsumoto M; Obayashi K; Hagiwara S; Murakoshi M; Aoki T; Wakabayashi M; Gohda T; Funabiki K; Maeda K; Horikoshi S; Tomino Y Nephrology (Carlton); 2006 Feb; 11(1):29-35. PubMed ID: 16509929 [TBL] [Abstract][Full Text] [Related]
2. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327 [TBL] [Abstract][Full Text] [Related]
3. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice. Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011 [TBL] [Abstract][Full Text] [Related]
4. Chromosomal mapping of a quantitative trait locus for the development of albuminuria in diabetic KK/Ta mice. Shike T; Gohda T; Tanimoto M; Kobayashi M; Makita Y; Funabiki K; Horikoshi S; Hirose S; Shirai T; Tomino Y Nephrol Dial Transplant; 2005 May; 20(5):879-85. PubMed ID: 15769825 [TBL] [Abstract][Full Text] [Related]
5. Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: involvement of anti-inflammation and antioxidative stress. Zhang M; Hagiwara S; Matsumoto M; Gu L; Tanimoto M; Nakamura S; Kaneko S; Gohda T; Qian J; Horikoshi S; Tomino Y Metabolism; 2006 Dec; 55(12):1590-8. PubMed ID: 17142129 [TBL] [Abstract][Full Text] [Related]
6. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998 [TBL] [Abstract][Full Text] [Related]
7. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats. Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956 [TBL] [Abstract][Full Text] [Related]
8. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Zheng F; He C; Cai W; Hattori M; Steffes M; Vlassara H Diabetes Metab Res Rev; 2002; 18(3):224-37. PubMed ID: 12112941 [TBL] [Abstract][Full Text] [Related]
9. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Hagiwara S; Makita Y; Gu L; Tanimoto M; Zhang M; Nakamura S; Kaneko S; Itoh T; Gohda T; Horikoshi S; Tomino Y Nephrol Dial Transplant; 2006 Mar; 21(3):605-15. PubMed ID: 16282336 [TBL] [Abstract][Full Text] [Related]
10. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice. Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690 [TBL] [Abstract][Full Text] [Related]
11. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice. Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441 [TBL] [Abstract][Full Text] [Related]
12. Hypoglycemic effect of hot-water extract of adzuki (Vigna angularis) in spontaneously diabetic KK-A(y) mice. Itoh T; Kobayashi M; Horio F; Furuichi Y Nutrition; 2009 Feb; 25(2):134-41. PubMed ID: 18929464 [TBL] [Abstract][Full Text] [Related]
13. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Schrijvers BF; Flyvbjerg A; Tilton RG; Lameire NH; De Vriese AS Nephrol Dial Transplant; 2006 Feb; 21(2):324-9. PubMed ID: 16249198 [TBL] [Abstract][Full Text] [Related]
14. Influence of C-peptide on early glomerular changes in diabetic mice. Maezawa Y; Yokote K; Sonezaki K; Fujimoto M; Kobayashi K; Kawamura H; Tokuyama T; Takemoto M; Ueda S; Kuwaki T; Mori S; Wahren J; Saito Y Diabetes Metab Res Rev; 2006; 22(4):313-22. PubMed ID: 16389646 [TBL] [Abstract][Full Text] [Related]
15. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Tsuchida K; Makita Z; Yamagishi S; Atsumi T; Miyoshi H; Obara S; Ishida M; Ishikawa S; Yasumura K; Koike T Diabetologia; 1999 May; 42(5):579-88. PubMed ID: 10333051 [TBL] [Abstract][Full Text] [Related]
16. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Tanimoto M; Fan Q; Gohda T; Shike T; Makita Y; Tomino Y Metabolism; 2004 Nov; 53(11):1473-9. PubMed ID: 15536604 [TBL] [Abstract][Full Text] [Related]
17. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus. Cha DR; Kim IS; Kang YS; Han SY; Han KH; Shin C; Ji YH; Kim NH Diabet Med; 2005 Jan; 22(1):14-20. PubMed ID: 15606685 [TBL] [Abstract][Full Text] [Related]
18. Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. Murakoshi M; Tanimoto M; Gohda T; Hagiwara S; Ohara I; Toyoda H; Ishikawa Y; Horikoshi S; Tomino Y Diabetes Res Clin Pract; 2009 Feb; 83(2):183-9. PubMed ID: 19144436 [TBL] [Abstract][Full Text] [Related]
19. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy. Ninichuk V; Kulkarni O; Clauss S; Anders H- Eur J Med Res; 2007 Aug; 12(8):351-5. PubMed ID: 17933712 [TBL] [Abstract][Full Text] [Related]
20. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Myint KM; Yamamoto Y; Doi T; Kato I; Harashima A; Yonekura H; Watanabe T; Shinohara H; Takeuchi M; Tsuneyama K; Hashimoto N; Asano M; Takasawa S; Okamoto H; Yamamoto H Diabetes; 2006 Sep; 55(9):2510-22. PubMed ID: 16936199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]